Evidence map›Paper›PMID 42013127›Full record

ReviewPLoS pathogens2026

Context-specific roles for IL-17 in tuberculosis.

Mahlatse Maseeme, Liku B Tezera, Mahdad Noursadeghi, Alasdair Leslie, Gabriele Pollara

Abstract readReview
In one paragraph

Review in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mahlatse MaseemeAfrica Health Research Institute, Durban, South Africa.
Liku B TezeraSchool of Clinical and Experimental Science, University of Southampton, Southampton, United Kingdom.
Mahdad NoursadeghiInstitute of Infection, Immunity & Transplantation, University College London, London, United Kingdom.
Alasdair LeslieAfrica Health Research Institute, Durban, South Africa.ORCID https://orcid.org/0000-0003-2538-6467
Gabriele PollaraInstitute of Infection, Immunity & Transplantation, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-5772-0322

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number 17 is considered unlucky by some Italians as its Roman numerals - XVII - can be rearranged as Vixi, a Latin expression that can be interpreted as "my life is over". In other contexts, the number 17 is associated with wisdom and success. This paradox holds true when it comes to the role of interleukin 17 (IL-17) in tuberculosis (TB). On one hand, immune correlates of protection studies have consistently identified IL-17 responses as key players in natural and vaccine induced protection against infection and disease. On the other, IL-17 has been proposed as a main driver of the immunopathology that underlies TB morbidity and mortality. Thus, while some researchers seek to develop novel TB vaccine approaches that promote IL-17 responses, others hunt for host-directed therapeutic approaches that block its activity. In this article, we attempt to address this conundrum and synthesise the main arguments supporting a role for IL-17 in the protection and pathogenesis of this deadly human infectious disease. Ultimately, as with superstition, whether the 17th interleukin is friend or foe in human TB is likely to depend on the context.

Indexed as

Interleukin-17Mycobacterium tuberculosisTuberculosisAnimalsHumansTuberculosis VaccinesInterleukin-17Tuberculosis Vaccines

Identifiers

PMID42013127
PMCPMC13098958

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.